Recent IFRX News
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 11:30:00 AM
- InflaRx Appoints Jan Medina as Head of Investor Relations • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 01:00:15 PM
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients • GlobeNewswire Inc. • 01/25/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 09:16:17 PM
- InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 01:00:09 PM
- InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum • GlobeNewswire Inc. • 11/06/2023 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 12:04:10 PM
- InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 12:45:50 PM
- InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 12:00:10 PM
- InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) • GlobeNewswire Inc. • 08/30/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 12:00:40 PM
- InflaRx Reports Second Quarter 2023 Financial Results & Operating Update • GlobeNewswire Inc. • 08/10/2023 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/12/2023 08:01:45 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/12/2023 04:15:08 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 06/30/2023 08:06:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 12:30:36 PM
- InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer • GlobeNewswire Inc. • 06/28/2023 11:30:00 AM
- InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients • GlobeNewswire Inc. • 06/21/2023 11:00:00 AM
- InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 05/11/2023 11:30:00 AM
- InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million • GlobeNewswire Inc. • 04/18/2023 08:01:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM